Clinical trial
Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
NCT01740271 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy
- Lead sponsor
- AHS Cancer Control Alberta
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 31, 2012
- Completion date
- June 30, 2025
- Enrollment
- 48 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.